BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Ruxolitinib: trial readouts and FDA decisions

2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 6 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Incyte Corporation, Ryvu Therapeutics SA, Kartos Therapeutics, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Ryvu Therapeutics SANCT06987058 RVU120 Rollover StudyAdvanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndromeenrolling by invitation14
2026-12-31 est.P3Kartos Therapeutics, Inc.NCT06479135 Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibMyelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis; MFrecruiting600

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-05 est.P2Incyte Corporation INCYNCT04509700 Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)B-Cell Malignanciesactive not recruiting112
2026-10-29P3Incyte Corporation INCYNCT06959225 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Hidradenitis Suppurativaactive not recruiting580
2026-10-01P3Incyte Corporation INCYNCT06958211 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Hidradenitis Suppurativaactive not recruiting573
2026-10-01P2Incyte Corporation INCYNCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseChronic Graft-versus-host-diseaseactive not recruiting130
2026-08-07P3Incyte Corporation INCYNCT06832618 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisAtopic Dermatitisactive not recruiting159
2026-06-30P2Ryvu Therapeutics SANCT06397313 RVU120 in Patients With Intermediate or High-risk, Primary or Secondary MyelofibrosisMyelofibrosisterminated36

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.